At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
Pamrevlumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating Pamrevlumab, Placebo, and 2 other interventions for Idiopathic Pulmonary Fibrosis. Completed, enrolled 160 participants across 42 sites in 7 countries.
Detailed Summary
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesAustralia, Bulgaria, Canada, India, New Zealand, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartJul 2013
Primary CompletionNov 2017
TodayJul 2026
First PostedJul 1, 2013
Enrollment StartJul 30, 2013
Primary CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 13.0 years ago
Interventions
Pamrevlumabdrug
Solution for infusion
Placebodrug
Solution for infusion
Sub-Study: Pirfenidonedrug
Pirfenidone concomitant therapy will not be provided by the Sponsor.
Sub-Study: Nintedanibdrug
Nintedanib concomitant therapy will not be provided by the Sponsor.